Christopher Gibson Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Christopher Gibson is Chief Executive Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 808,738 shares of RXRX, which is worth approximately $6.7 Million. The most recent transaction as insider was on May 15, 2024, when has been sold 26,082 shares (Class A Common Stock) at a price of $10.01 per share, resulting in proceeds of $261,080. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 809K

26.81% 3M change

14.11% 12M change

Total Value Held $6.7 Million

Christopher Gibson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 15 2024	SELL Payment of exercise price or tax liability	$261,080 $10.01 p/Share	26,082 Reduced 3.12%	808,738 Class A Common Stock
May 02 2024	SELL Open market or private sale	$423,500 $8.47 p/Share	50,000 Reduced 5.65%	834,820 Class A Common Stock
May 02 2024	BUY Conversion of derivative security	-	21,296 Added 2.43%	856,116 Class A Common Stock
May 01 2024	SELL Open market or private sale	$386,500 $7.73 p/Share	50,000 Reduced 5.47%	863,524 Class A Common Stock
May 01 2024	SELL Bona fide gift	-	25,000 Reduced 2.66%	913,524 Class A Common Stock
Apr 04 2024	SELL Open market or private sale	$360,800 $9.02 p/Share	40,000 Reduced 4.09%	938,524 Class A Common Stock
Apr 03 2024	SELL Open market or private sale	$353,600 $8.84 p/Share	40,000 Reduced 3.93%	978,524 Class A Common Stock

Apr 03 2024	SELL Bona fide gift	-	25,000 Reduced 2.4%	1,018,524 Class A Common Stock
Mar 28 2024	SELL Bona fide gift	-	25,000 Reduced 2.26%	1,083,524 Class A Common Stock
Mar 28 2024	SELL Open market or private sale	$404,000 $10.1 p/Share	40,000 Reduced 3.69%	1,043,524 Class A Common Stock
Mar 06 2024	SELL Bona fide gift	-	10,000 Reduced 0.9%	1,104,919 Class A Common Stock
Mar 06 2024	SELL Open market or private sale	$430,743 $11.86 p/Share	36,319 Reduced 3.17%	1,108,524 Class A Common Stock
Mar 06 2024	BUY Conversion of derivative security	-	10,000 Added 0.89%	1,114,919 Class A Common Stock
Mar 06 2024	BUY Exercise of conversion of derivative security	$277,072 $6.94 p/Share	39,924 Added 3.37%	1,144,843 Class A Common Stock
Feb 15 2024	SELL Payment of exercise price or tax liability	$138,569 $12.43 p/Share	11,148 Reduced 1.0%	1,104,919 Class A Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$32,620 $10.09 p/Share	3,233 Reduced 0.29%	1,116,067 Class A Common Stock
Feb 09 2024	BUY Grant, award, or other acquisition	-	344,597 Added 23.54%	1,119,300 Class A Common Stock
Feb 07 2024	SELL Bona fide gift	-	10,000 Reduced 1.25%	791,725 Class A Common Stock
Feb 07 2024	SELL Open market or private sale	$445,067 $9.22 p/Share	48,272 Reduced 5.87%	774,703 Class A Common Stock
Feb 07 2024	BUY Conversion of derivative security	-	10,000 Added 1.23%	801,725 Class A Common Stock
Feb 07 2024	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 3.66%	822,975 Class A Common Stock
Jan 03 2024	SELL Open market or private sale	$292,794 $9.49 p/Share	30,853 Reduced 3.75%	791,725 Class A Common Stock
Jan 03 2024	SELL Bona fide gift	-	10,000 Reduced 1.25%	791,328 Class A Common Stock
Jan 03 2024	BUY Conversion of derivative security	-	10,000 Added 1.23%	801,328 Class A Common Stock
Jan 03 2024	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 3.66%	822,578 Class A Common Stock

Christopher Gibson

Chief Executive Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account